Hedgehog Signaling in Cancer Stem Cells: a Focus on Hematological Cancers

Overview

Journal Stem Cells Cloning

Publisher Dove Medical Press

Specialty Biotechnology

Date 2015 Feb 19

PMID 25691811

Citations 35

Authors

Victoria Campbell

Mhairi Copland

Affiliations

Soon will be listed here.

Abstract

The stem cell paradigm was first demonstrated in hematopoietic stem cells. Whilst classically it was cytokines and chemokines which were believed to control stem cell fate, more recently it has become apparent that the stem cell niche and highly conserved embryonic pathways play a key role in governing stem cell behavior. One of these pathways, the hedgehog signaling pathway, found in all organisms, is vitally important in embryogenesis, performing the function of patterning through early stages of development, and in adulthood, through the control of somatic stem cell numbers. In addition to these roles in health however, it has been found to be deregulated in a number of solid and hematological malignancies, components of the hedgehog pathway being associated with a poor prognosis. Further, these components represent viable therapeutic targets, with inhibition from a drug development perspective being readily achieved, making the hedgehog pathway an attractive potential therapeutic target. However, although the concept of cancer stem cells is well established, how these cells arise and the factors which influence their behavior are not yet fully understood. The role of the hedgehog signaling pathway and its potential as a therapeutic target in hematological malignancies is the focus of this review.

Citing Articles

RNA modification in normal hematopoiesis and hematologic malignancies.

Chen X, Yuan Y, Zhou F, Li L, Pu J, Jiang X MedComm (2020). 2024; 5(11):e787.

PMID: 39445003 PMC: 11496571. DOI: 10.1002/mco2.787.

The Role of Mutated Calreticulin in the Pathogenesis of -Negative Myeloproliferative Neoplasms.

Vadeikiene R, Jakstys B, Laukaitiene D, Satkauskas S, Juozaityte E, Ugenskiene R Int J Mol Sci. 2024; 25(18).

PMID: 39337361 PMC: 11432199. DOI: 10.3390/ijms25189873.

Dynein axonemal heavy chain 9 M4374I variation may have an effect on imatinib mesylate resistance in CML.

Yildirim M, Si Msek L, Zamani A, Ceneli O, Demi Rci Oglu S Med Int (Lond). 2024; 2(1):4.

PMID: 38938903 PMC: 11208984. DOI: 10.3892/mi.2022.29.

Re-Sensitizing Cancer Stem Cells to Conventional Chemotherapy Agents.

Kim M, Bakyt L, Akhmetkaliyev A, Toktarkhanova D, Bulanin D Int J Mol Sci. 2023; 24(3).

PMID: 36768445 PMC: 9917165. DOI: 10.3390/ijms24032122.

Influence of Long Non-Coding RNA in the Regulation of Cancer Stem Cell Signaling Pathways.

Sonawala K, Ramalingam S, Sellamuthu I Cells. 2022; 11(21).

PMID: 36359888 PMC: 9656902. DOI: 10.3390/cells11213492.

References

Bhardwaj G, Murdoch B, Wu D, Baker D, Williams K, Chadwick K . Sonic hedgehog induces the proliferation of primitive human hematopoietic cells via BMP regulation. Nat Immunol. 2001; 2(2):172-80. DOI: 10.1038/84282. View

Clevers H . The cancer stem cell: premises, promises and challenges. Nat Med. 2011; 17(3):313-9. DOI: 10.1038/nm.2304. View

Singh R, Kim J, Davuluri Y, Drakos E, Cho-Vega J, Amin H . Hedgehog signaling pathway is activated in diffuse large B-cell lymphoma and contributes to tumor cell survival and proliferation. Leukemia. 2010; 24(5):1025-36. DOI: 10.1038/leu.2010.35. View

Hegde G, Nordgren T, Munger C, Mittal A, Bierman P, Weisenburger D . Novel therapy for therapy-resistant mantle cell lymphoma: multipronged approach with targeting of hedgehog signaling. Int J Cancer. 2012; 131(12):2951-60. DOI: 10.1002/ijc.27602. View

Bernt K, Armstrong S . Leukemia stem cells and human acute lymphoblastic leukemia. Semin Hematol. 2008; 46(1):33-8. PMC: 4031465. DOI: 10.1053/j.seminhematol.2008.09.010. View

Martin S, Sato N, Dhara S, Chang R, Hustinx S, Abe T . Aberrant methylation of the Human Hedgehog interacting protein (HHIP) gene in pancreatic neoplasms. Cancer Biol Ther. 2005; 4(7):728-33. DOI: 10.4161/cbt.4.7.1802. View

Kim J, Lee J, Kim J, Gardner D, Beachy P . Arsenic antagonizes the Hedgehog pathway by preventing ciliary accumulation and reducing stability of the Gli2 transcriptional effector. Proc Natl Acad Sci U S A. 2010; 107(30):13432-7. PMC: 2922148. DOI: 10.1073/pnas.1006822107. View

Cooper M, Porter J, Young K, Beachy P . Teratogen-mediated inhibition of target tissue response to Shh signaling. Science. 1998; 280(5369):1603-7. DOI: 10.1126/science.280.5369.1603. View

Canettieri G, Di Marcotullio L, Coni S, Greco A, Gulino A . Turning off the switch in medulloblastoma: the inhibitory acetylation of an oncogene. Cell Cycle. 2010; 9(11):2047-8. DOI: 10.4161/cc.9.11.11860. View

10.

Buglino J, Resh M . Hhat is a palmitoylacyltransferase with specificity for N-palmitoylation of Sonic Hedgehog. J Biol Chem. 2008; 283(32):22076-88. PMC: 2494920. DOI: 10.1074/jbc.M803901200. View

11.

Patole S, Patole A, Rhen D, Shahid M, Min H, Joon Kang D . Patterned carbon nanotube growth using an electron beam sensitive direct writable catalyst. Nanotechnology. 2009; 20(31):315302. DOI: 10.1088/0957-4484/20/31/315302. View

12.

Incardona J, Gaffield W, Lange Y, Cooney A, Pentchev P, Liu S . Cyclopamine inhibition of Sonic hedgehog signal transduction is not mediated through effects on cholesterol transport. Dev Biol. 2000; 224(2):440-52. DOI: 10.1006/dbio.2000.9775. View

13.

Rohner A, Spilker M, Lam J, Pascual B, Bartkowski D, Li Q . Effective targeting of Hedgehog signaling in a medulloblastoma model with PF-5274857, a potent and selective Smoothened antagonist that penetrates the blood-brain barrier. Mol Cancer Ther. 2011; 11(1):57-65. DOI: 10.1158/1535-7163.MCT-11-0691. View

14.

Hochhaus A, Hughes T . Clinical resistance to imatinib: mechanisms and implications. Hematol Oncol Clin North Am. 2004; 18(3):641-56, ix. DOI: 10.1016/j.hoc.2004.03.001. View

15.

Carpenter D, Stone D, Brush J, Ryan A, Armanini M, Frantz G . Characterization of two patched receptors for the vertebrate hedgehog protein family. Proc Natl Acad Sci U S A. 1998; 95(23):13630-4. PMC: 24870. DOI: 10.1073/pnas.95.23.13630. View

16.

Hochhaus A, OBrien S, Guilhot F, Druker B, Branford S, Foroni L . Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia. Leukemia. 2009; 23(6):1054-61. DOI: 10.1038/leu.2009.38. View

17.

Sasaki K, Gotlib J, Mesa R, Newberry K, Ravandi F, Cortes J . Phase II evaluation of IPI-926, an oral Hedgehog inhibitor, in patients with myelofibrosis. Leuk Lymphoma. 2015; 56(7):2092-7. PMC: 4919663. DOI: 10.3109/10428194.2014.984703. View

18.

le Viseur C, Hotfilder M, Bomken S, Wilson K, Rottgers S, Schrauder A . In childhood acute lymphoblastic leukemia, blasts at different stages of immunophenotypic maturation have stem cell properties. Cancer Cell. 2008; 14(1):47-58. PMC: 2572185. DOI: 10.1016/j.ccr.2008.05.015. View

19.

Lee J, Ekker S, von Kessler D, Porter J, Sun B, Beachy P . Autoproteolysis in hedgehog protein biogenesis. Science. 1994; 266(5190):1528-37. DOI: 10.1126/science.7985023. View

20.

Ohashi T, Oguro Y, Tanaka T, Shiokawa Z, Tanaka Y, Shibata S . Discovery of the investigational drug TAK-441, a pyrrolo[3,2-c]pyridine derivative, as a highly potent and orally active hedgehog signaling inhibitor: modification of the core skeleton for improved solubility. Bioorg Med Chem. 2012; 20(18):5507-17. DOI: 10.1016/j.bmc.2012.07.034. View